Spondin-2 (SPON2)

Spondin-2 (SPON2) is a secreted extracellular matrix protein belonging to the F-spondin family, encoded by the SPON2 gene. It is involved in numerous physiological and pathological functions across development, immunity, and cancer biology. SPON2 serves as a broad-spectrum tumor marker, particularly with application in prostate cancer where its serum levels outperform traditional biomarkers such as PSA for diagnostic accuracy. Functionally, SPON2 regulates growth, tissue morphogenesis (notably in craniofacial and limb development), osteoblast differentiation and bone metabolism, and the innate immune response through recruitment and activation of inflammatory cells. In cancer, SPON2 acts as an oncogene in most tumors, promoting proliferation, migration, invasion, and metastasis (including the formation of osteoclastic niches for bone metastasis), though it functions as a tumor suppressor in select contexts such as liver and colorectal cancer. Mechanistically, SPON2 interacts with integrin α5β1 and LGR4/5/6, modulating major oncogenic and developmental signaling pathways such as WNT/β-catenin, PI3K/AKT/mTOR, FAK/SRC, NF-κB, Notch, and Hippo/Yap, which govern its diverse effects[1][2][3][4]. No therapeutics specifically targeting SPON2 are currently in clinical use, but its important role in cancer progression, immune regulation, and tissue homeostasis make it a compelling candidate for future therapeutic and diagnostic development.

Other names

Spondin-2SPON2MindinM-spondinDIL-1DIL1UNQ435/PRO866differentially expressed in cancerous and non-cancerous lung cells 1M-SPONDINMINDIN

No drugs with characterized mechanisms of action targeting Spondin-2 identified; molecular action involves regulation of signaling pathways (WNT/β-catenin, PI3K/AKT/mTOR, NF-κB, FAK/SRC, Notch, Hippo/Yap, MAPK, among others)[1][2][4].